📌 Key Takeaways
- Topic: Mica Powder vs Silica: Properties and Applications Compared
- Keywords: kaolin
- Published: 2026-11-20 01:01:19
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Angular Silica Powder: Properties, Uses and When to Choose It Over Spherical Silica
- Cosmetic Grade Silica: Types, Benefits and Uses in Skincare and Makeup
- Clinical trials involving mesoporous silica have been ongoing since 2007, discussing its potential in diverse biomedical applications (Table 3 ). To date, the clinical trials have revealed the safety and good tolerability of silica in human subjects. In 2014, MSNs as oral delivery carriers for boosting the pharmacokinetic profile of drugs with limited aqueous solubility were reported. 500 A silica NPs-lipid hybrid formulation loading with ibuprofen (Lipoceramic-IBU) was prepared. The randomized, double-blind, single-dose oral administration study (20 mg ibuprofen) was conducted on 16 healthy male volunteers. The bioavailability of Lipoceramic-IBU was found to be 1.95 times higher than that of the commercial tablet Nurofen. 500 This result suggested the secure and effective use of silica-based NPs in mimicking food impacts to optimize the oral absorption of drugs with poor water solubility. In another clinical trial consisting of 12 participants in 2016, the bioavailability of ordered MSNs-based fenofibrate formulation raised by 54.1% after a single oral dose, when compared to the commercial formulation Lipanthyl. 39 Owing to the potentially perfect clinical outcomes of silica-based nanocarriers, the pharmacokinetics, safety, and metabolic profile of a hybrid core-shell silica NP (named Cornell dots, C dots) with a diameter of 6 nm functionalized with 124 I, targeting peptide cyclo-(Arg-Gly-Asp-Tyr), and Cy5 ( 124 I-cRGDY-PEG-C' dots) is first conducted in humans utilizing PET imaging and clinical tracer at clinical trials in 2014 (NCT01266096). 58 Results showed the good safety and reproducible PK signatures of C dots with the whole-body clearance half-time of 13-21 h after intravenous administration in patients, which is shorter than 111 In labeled liposomes and 131 I-labeled humanized monoclonal antibody A33. These findings verified the possibility of these NPs for cancer diagnostics in humans. 58 Similarly, 8 nm core-shell silica NPs encapsulated with Cy5.5 in the core and connected with cRGDY on the surface (cRGDY-PEG-Cy5.5-nanoparticles) were used in patients at nanomole doses for sentinel lymph nodes detection of head and neck melanoma at a phase 1/2 human clinical trial. 501 The incredible safety, accuracy, reliability, and high contrast of these particles for visual identification of sentinel lymph nodes are irreplaceable by other available imaging molecules presently, of which phase 2 clinical trial is ongoing and will be finished in 2024 (NCT02106598). Meanwhile, another two clinical trials based on C dots are carried out. In 2018, the 89 Zr-DFO-cRGDY-PEG-Cy5-C' dots tracers were first used in both surgical and non-surgical patients for PET-CT imaging of malignant brain tumors in phase 1 clinical trial (NCT03465618). The distribution and removal profiles from the body of these particles will also be assessed till 2023. In 2019, 64 Cu-NOTA-PSMA-PEG-Cy5.5-C' dots tracer was used in another human phase 1 clinical trial for guiding the surgery of prostate cancer by PET and MRI imaging (NCT04167969).As a nanocomposite with high safety and brilliant photothermal conversion efficiency, the silica-gold NPs have also been shown to be potential therapeutic agents for plasmonic photothermal therapy of atherosclerosis (NCT01270139), 502, 503 and photothermal ablation of tumors (NCT00848042, NCT04240639). 40 In addition, an engineered mesoporous silica (SiPore15) with particle size of 1.1-1.5 μm × 0.2-0.4 μm was developed by Baek et al., and they revealed that such pure synthetic amorphous silica could remarkably decrease long-term blood glucose levels, showing good promise for the treatment of prediabetes (NCT03823027). 504 In other clinical trials, an amorphous silica-containing bioactive scaffold, called Siloss, was used to promote bone regeneration, and could be replaced by natural bone due to its fully resorbable nature (NCT02639572), and the silica-calcium phosphate nanocomposite (SCPC) was developed as graft material for the reconstruction of the volume-deficient alveolar ridges (NCT05317039). In all, these clinical trials reveal the safety and efficacy of MSNs in diverse biomedical application scenarios.
- Silica Supplier Thailand: Market Overview and Sourcing Options
- What Is the Common Name for Silicon Dioxide? Silica, Quartz and Other Names
- Alison, L. et al. Pickering and network stabilization of biocompatible emulsions using chitosan-modified silica nanoparticles. Langmuir 32, 13446-13457 (2016). Post CAS PubMed Google Scholar
- What Is Silicon Dioxide (SiO₂)? Structure, Properties, Types and Uses Explained
What Is Pyrogenic Silica? How It Is Made and Why It Is Used as a Thickener
What is silica (SiO₂)?
silicon nitride Generally speaking, MSNs are often manufactured via surfactant-templating sol-gel method. Their structure and morphology are influenced by different factors, i.e., surfactants, silica sources, reaction catalysts, and other external reaction conditions such as pH and temperature. 62, 63, 64 Of these, the surfactants as the structure-directing agents play a crucial part in determining the mesoporous architectures of MSNs, since they can induce the micellization of foam during the reaction process. 65 Three main categories of structure-directing agents are frequently used in the synthesis of MSNs, including cationic surfactants (e.g., CTAB and cetyltrimethylammonium chloride (CTAC)), anionic surfactants (e.g., phosphoric acid, sodium dodecyl sulfate, and alkyl carboxylic acid), and non-ionic surfactants (Pluronic F123, F127, polyethylene oxide (PEO) and polypropylene oxide (PPO)). 66 Because of the diversity of surfactants, diverse MSNs with distinctive configurations have been created and received phenomenal attention from researchers. Presently, MSNs can be divided into M41S-series, SBA-series, Fudan University (FDU)-series, and Korea Institute of Technology (KIT)-series, etc, according to the mesoporous materials family. Table 1 summarizes some of the more well-studied types of MSNs. These different families of mesoporous silicas are detailed as follows.
What is the difference between fumed silica and precipitated silica?
silica exposure limit
What drives silica raw material prices?
does silicon dioxide conduct electricity Gschwend, P. M., Conti, S., Kaech, A., Maake, C. & Pratsinis, S. E. Silica-coated TiN particles for killing cancer cells. ACS Appl. Mater. Interfac. 11, 22550-22560 (2019). Piece CAS Google Scholar
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.